Antibodies for Alzheimer’s Disease - FocusOn 130
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by dementia that generally initiates with subtle failure of memory, progressing over years to an incapacitating level. Approximately 25 % of all AD is familial of which approximately 95 % is late-onset (age >60-65 years) and 5 % is early-onset (age <60 years).
The generation of the Amyloid-β (Aβ) peptide through the proteolytic processing of the Amyloid precursor protein (APP) is a central event in the pathogenesis of AD. Extracellular accumulation of Aβ leads to formation of aggregates, fibrils and eventually amyloid deposits called neuritic plaques, a hallmark of AD. The Aβ peptide has neurotoxic effects and AD research has been focused on determining the underlying mechanisms of Aβ protein toxicity.
Established candidates for the cleavage of APP to Aβ are the β-secretases BACE1 and BACE2 and Presenilin 1 and 2, which resemble the catalytic subunit of the γ-secretase complex . PEN2 (presenilin enhancer 2) is the regulatory component of the γ-secretase complex.
Ubiquilin 1 (UBQLN1) is a ubiquitin-like protein, which has been shown to play a central role in regulating the proteasomal degradation of various proteins, including the presenilins. A role for UBQLN1 steady-state levels in affecting APP trafficking and processing has been proposed, thereby influencing the generation of Aβ.
Amyloid protein-binding protein 1 (APPBP1) and Amyloid protein-binding protein 2 (APPBP2) interact with APP and are functionally associated with APP transport and/or processing.
Three alleles for Apolipoprotein E (ApoE) are known and there is a strong association of one or two copies of the ApoE allele e4 with late-onset AD, although the mechanism by which this allele impacts AD remains unproven.
Apolipoprotein E receptor 2 (ApoER2) is a member of the LDL receptor family that is highly expressed in the brain. It has been shown that ApoER2 expression stimulates Aβ production by enhanced β- and γ-secretase mediated amyloidogenic processing.
Clusterin/apolipoprotein J (Apo J) has also been identified as a potential risk gene in AD. Elevated protein levels are found in the CNS under some neuropathological conditions, such as AD, where Apo J is associated with Aβ plaques.
Microtubule-associated protein tau (MAPT/Tau) is a neuronal microtubule associated protein and it promotes tubulin polymerization and stabilizes microtubules. In its hyperphosphorylated form, tau is the major component of paired helical filaments and neurofibrillary lesions in AD brain. Hyperphosphorylation impairs the microtubule binding function of tau, resulting in the destabilization of microtubules in AD brains, ultimately leading to the degeneration of the affected neurons.
Cyclin-dependent kinase 5 activator 1 (CDK5R1) activates CDK5, which is required for proper development of the central nervous system. CDK5R1 is cleaved from a p35 into a p25 form and has been shown to accumulate in neurons of patients with AD. This accumulation correlates with an increase in CDK5 activity and may lead to aberrantly phosphorylated forms of MAPT/TAU, which contributes to AD.
Alpha 1-antichymotrypsin (ACT) has been shown to promote Aβ polymerization and levels of ACT protein in plasma and cerebrospinal fluid from Alzheimer‘s patients have been found to correlate with progression of dementia. ACT may lead to hyperphosphorylation of tau thereby enhancing degeneration of neurons.
Calsenilin and KCNIP1/VABP are members of the family of voltage-gated potassium channel-interacting proteins. They interact with presenilin 1 and 2 and are implicated in the mediation of Aβ formation.
Brain-derived neurotrophic factor (BDNF) belongs to so-called neurotrophins and supports the survival of existing neurons and encourages the growth and differentiation of new neurons. Neurotrophins are thought to have a protective role against Aβ toxicity.
Detection of Neurofilament M can be used in studies to visualize neurofilament accumulation as it can be seen in AD.
In AD, microglial expression of Macrophage scavenger receptor 1 ( MSR1/CD204) is increased. Findings of CD204 mediated adhesion and endocytosis of fibrillar Aβ by microglia and astrocytes suggest a role for this receptor in neuronal homeostasis and neuropathology.
Il-1 is a cytokine which is overexpressed in the AD brain. This correlates to plaque formation and progression by leading to excessive expression of neuronal APP and other plaque-associated proteins and to nonsensical growth of dystrophic neuritis. Polymorphism in the IL-1A and IL-1B genes are discussed for early age onset AD.
Kallikrein-6 is a serin protease and abnormal levels have been found in patients with AD. The potential role of Kallikrein-6 as a biomarker for AD is under investigation and it has been reported that this protein might play a role in the degradation of Aß or turnover of APP.
Homeobox protein MOX-2 (MEOX2) is a regulator of vascular differentiation and its expression is low in AD. It has been shown that restoring expression of the protein stimulates angiogenesis, suppresses apoptosis and increases the levels of a major Aβ clearance receptor, the low-density lipoprotein receptor-related protein 1 (LRP), at the blood-brain barrier.
Bax, a pro-apoptotic protein belonging to the Bcl-2 family, promotes increased apoptosis leading to enhanced neuronal degeneration in progression of AD. Bax may play a similar role in Huntington's disease.
Humanin and its homologue in rats, Rattin, have been shown to suppress the onset of AD-related dementia by inhibiting both AD-related neuronal cell death and dysfunction. Humanin diminishes aggregation and fibrillary formation by suppressing the effect of APP on mononuclear phagocytes and competitively inhibiting the binding of APP to the formyl peptide receptor-like-1 (FPRL1).
While in AD there is abundant evidence for the involvement of oxidative stress, the cause or the consequences are largely unresolved. NAD(P)H dehydrogenase (quinone 1) (NQO1), a redox-regulated flavoenzyme, plays a central role in monitoring cellular redox state and has been shown to be increased in AD.
Recent studies reveal complement component (3b/4b) receptor 1 (CR1) and phosphatidylinositol binding clathrin assembly protein (PICALM) as potential risk genes in AD. Results for CR1 indicate a role in the clearance of Aβ, but the importance of CR1 and PICALM proteins in AD remains to be elucidated.
- Carrión, AM, 1998, Mol Cell Biol
- Corneveaux, JJ, 2010, Hum Mol Genet
- Fuentealba, RA, 2007, Mol Neurodegener
- Hiltunen, M, 2006, J Biol Chem
- Husemann, J, 2002, Glia
- Lambert, J, 2009, Nat Genet
- Matsuoka, M, 2010, Mol Neurobiol
- Mrak, RE, 2001, Neurobiol Aging
- Ogawa, K, 2000, Psychiatry Clin Neurosci
- Padmanabhan, P, 2006, Brain
- Raina AK, 1999, Redox Rep
- Smith, FP, 2005, Nat Med
- Studzinski, GP and Harrison JS, 2003, Leuk Lymphoma
See the PDF-version: FocusOn 130